NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee C meeting minutes

**Minutes:** Unconfirmed

**Date:** Tuesday 6 December 2022

**Location:** Via Zoom

## Attendees

Committee members present

1. Professor Stephen O’Brien (Chair) Present for all items
2. Dr Richard Nicholas (Vice Chair) Present for all items
3. Iftab Akram Present for all items
4. Dr Alex Cale Present for all items
5. Michael Chambers Present for all items
6. Dr Prithwiraj Das Present for all items
7. Chamkhor Dhillon Present for all items
8. Dr Rob Forsyth Present for all items
9. Dr Pedro Saramago Goncalves Present for all items
10. Dr Natalie Hallas Present for all items
11. John Hampson Present for all items
12. Dr Nigel Langford Present for all items
13. Dr Andrea Manca Present for all items
14. Iain McGowan Present for all items
15. Stella O’Brien Present for all items
16. Professor Subhash Pokhrel Present for all items
17. Professor Andrew Renehan Present for all items
18. Dr Arpit Srivastava Present for all items
19. Professor Matthew Stevenson Present for all items
20. Professor Paul Tappenden Present for all items
21. Dr Derek Ward Present for all items

NICE staff (key players) present

Ross Dent, Associate Director Present for all items

Louise Jafferally, Project Manager Present for all items

Louise Crathorne, Heath Technology Assessment Adviser Present for all items

Catherine Spanswick, Heath Technology Assessment Analyst Present for all items

Benjamin Gregory, Business Analyst, RIA Present for all items

Sarah Bromley, Senior Medical Editor Present for all items

Ella Fitzpatrick, Public Involvement Adviser, PIP Items 1 to 4.1.3

Emma Gordon, Coordinator, MIP Items 1 to 4.1.3

Gemma Smith, Coordinator, COT Present for all items

Iain Cannell, Administrator, TA Present for all items

NICE staff (observers) present

Carl Prescott, Health Technology Assessment Adviser, TA Present for all items

Sarah Wilkes, Technical Analyst, Commercial Liaison team Present for all items

Catrin Austin, Technical Analyst, Evidence Generation Present for all items

Ian Watson, Heath Technology Assessment Adviser – Methods Present for all items

Carl Jackson, Assistant Project Manager, COT Present for all items

Denise Moyo, Coordinator, COT Present for all items

External assessment group representatives present

Daniel Gallacher, Warwick Evidence Items 1 to 4.2.1

Mandy Maredza, Warwick Evidence Items 1 to 4.2.1

Clinical, Patient & NHS England experts present

Dr Mark Bishton, Associate Professor and Honorary Consultant in Haematology, clinical expert, nominated by NCRI-ACP-RCP-RCR, Items 1 to 4.1.3

Professor Peter Clark, Cancer Drug Fund Clinical Lead, NHS England, Items 1 to 4.1.3

Zoe Drymoussi, Patient expert nominated by the Follicular Lymphoma Foundation, Items 1 to 4.1.3

Dr Kim Linton, Clinical Senior Lecturer and Honorary Consultant in Medical Oncology, clinical expert, nominated by Roche Products Ltd, Items 1 to 4.1.3

## Minutes

### Introduction to the meeting

* 1. The Professor Stephen O’Brien welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Dr David Foreman and Ugochi Nwulu.

### News and announcements

* 1. Committee said goodbye to Dr Derek Ward and Professor Subhash Pokhrel who are stepping down from committee with this being there last meeting.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 1 November 2022

### Appraisal of Mosunetuzumab for treating relapsed or refractory follicular lymphoma [ID3931]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Roche Products Ltd.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Michael Chambers declared a financial interest as he has coordinated a training programme (University of Utrecht) on Real World Evidence for Roche. This did not include any consideration of Roche products. It was agreed that his declaration would not prevent Michael from participating in discussions on this appraisal.
* Committee member Dr Richard Nicholas declared a financial interest as he has carried out advisory board with Roche in an unrelated disease area - multiple sclerosis. It was agreed that his declaration would not prevent Dr Richard Nicholas from participating in discussions on this appraisal
* Nominated clinical expert Dr Kim Linton declared a financial interest as she has received financial remuneration from Celgene, Beigene, Roche, Kite/Gilead, and Genmab for advisory board work. It was agreed that her declaration would not prevent Dr Linton from providing expert advice to the committee.
* Nominated clinical expert Dr Mark Bishton declared financial interests as he has received financial remuneration from Celgene, Beigene, Roche, Kite/Gilead, and Genmab for advisory board work. It was agreed that his declaration would not prevent Dr Bishton from providing expert advice to the committee.
* No further interests were declared for this appraisal.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Derek Ward & Michael Chambers.
  1. Part 2a – Closed session (company representatives, clinical and patient experts, and members of the public were asked to leave the meeting).
     1. The committee discussed confidential information submitted for this item.
  2. Part 2b – Closed session (external assessment group representatives were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached through a vote by members.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10816>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee C will be held on Tuesday 17 January 2022 and will start promptly at 09:30.